Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY: TEVA )

16.48 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,458
Open 16.48
Bid (Size) 16.37 (1)
Ask (Size) 16.41 (2)
Prev. Close 16.48
Today's Range 16.48 - 16.48
52wk Range 12.51 - 22.80
Shares Outstanding 1,110,352,397
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Forecasting The Future: 6 Analyst Projections For Teva Pharmaceutical Indus
Via Benzinga
Is SoundHound AI Stock a Buy Now?
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence

Performance

YTD
-22.63%
-22.63%
1 Month
-1.96%
-1.96%
3 Month
-5.56%
-5.56%
6 Month
-8.24%
-8.24%
1 Year
+22.16%
+22.16%

More News

Read More
Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Spotlight on Teva Pharmaceutical Indus: Analyzing the Surge in Options Activity
Via Benzinga
Teva Pharmaceutical Indus Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder
From Teva Pharmaceutical Industries Ltd; Medincell
Via GlobeNewswire
Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease
Via Benzinga
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
What Analysts Are Saying About Teva Pharmaceutical Indus Stock
Via Benzinga
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Billionaire Stanley Druckenmiller Dumped Duquesne's Entire Stake in Broadcom and Bought One of Wall Street's Hottest Drug Stocks Hand Over Fist
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
From Teva Pharmaceutical Industries Ltd; Alvotech
Via GlobeNewswire
Billionaire Investor Stanley Druckenmiller Dumps Broadcom, Bets Big On Tesla, Amazon And Other Big Tech Stocks In Q4
Via Benzinga
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?
Via Benzinga
This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy?
Via The Motley Fool
Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
MarketBeat Week in Review – 02/03 - 02/07
Via MarketBeat
Topics Artificial Intelligence Economy World Trade
Exposures Artificial Intelligence Interest Rates Tariff
Neurocrine Biosciences Reports Mixed Q4
Via The Motley Fool
Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now
Via MarketBeat
NVIDIA, Teva Pharmaceutical And UPS Are Among Top Large Cap Losers Last Week (Jan 27-Jan 31): Are The Others In Your Portfolio?
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Teva Pharmaceutical Stock Is Sinking Today
Via The Motley Fool
Teva Pharmaceutical Industries (TEVA) Q4 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Crude Oil Down 1.5%; Teva Pharmaceutical Shares Plummet
Via Benzinga
Exposures Fossil Fuels
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.